Search

Background Adding radiotherapy (RT) to systemic therapy improves progression-free survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer (NSCLC). Whether these findings translate to epidermal growth factor receptor (EGFR)–mutated NSCLC remains unknown. The SINDAS trial (NCT02893332) evaluated first-line tyrosine kinase inhibitor (TKI) therapy for EGFR -mutated synchronous oligometastatic NSCLC and randomized to upfront RT vs no RT; we now report the prespecified interim analysis at 68% accrual. Methods Inclusion criteria were biopsy-proven EGFR -mutated adenocarcinoma (per amplification refractory mutation system or next generation sequencing), with synchronous (newly diagnosed, treatment naïve) oligometastatic (≤5 metastases; ≤2 lesions in any one organ) NSCLC without brain metastases. All patients received a first-generation TKI (gefitinib, erlotinib, or icotinib), and randomization was between no RT vs RT (25-40 Gy in 5 fractions depending on tumor size and location) to all metastases and the primary tumor/involved regional lymphatics. The primary endpoint (intention to treat) was PFS. Secondary endpoints included OS and toxicities. All statistical tests were 2-sided. Results A total of 133 patients (n = 65 TKI only, n = 68 TKI with RT) were enrolled (2016-2019). The median follow-up was 23.6 months. The respective median PFS was 12.5 months vs 20.2 months (P  < .001), and the median OS was 17.4 months vs 25.5 months (P  < .001) for TKI only vs TKI with RT. Treatment yielded no grade 5 events and a 6% rate of symptomatic grade 3-4 pneumonitis in the TKI with RT arm. Based on the efficacy results of this prespecified interim analysis, the ethics committee recommended premature cessation of this trial. Conclusions As compared with a first-line TKI alone, addition of upfront local therapy using RT statistically significantly improved PFS and OS for EGFR -mutated NSCLC. [ABSTRACT FROM AUTHOR]

A new type of polyimide foam (PIF) was prepared and characterized based on a one-pot process by the reaction of a first solution with different ratios of a second solution. The first solution was comprised of pyromellitic dianhydride (PMDA), N, N-dimethyl formamide (DMF), methanol, water, surfactant, and catalysts, while the second solution contained polyaryl polymethylene isocyanate (PAPI). In the present study, the relationships among compositions, structures, and properties of PIFs were investigated. The results indicated that with the increase in the weight ratio of PAPI/(first solution), the foaming degrees of PIFs increased from 10.14 to 10.52 times and the apparent densities before postcure decreased from 15.96 to 14.51 kg/m3. The open cell contents, average sound absorption coefficients, and average cellular diameters of PIFs after postcure increased with increase in the weight ratio of PAPI/(first solution). The glass transition temperatures ( Tg) of PIFs after postcure first increased from 287 to 299°C, then decreased to 292°C, and the 5% weight loss temperatures and 10% weight loss temperatures presented the same trend as well. The compressive and flatwise tensile properties scaled very well with the relative densities of the foams after postcure, with the highest compressive strength of 0.03 MPa and the highest flatwise tensile strength of 0.15 MPa. Copyright © 2011 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Objective: To investigate the regulatory effect of miR-126 on epidermal growth factor-like domain 7 (EGFL7) in ECV-304 cells., Methods: The miR-126-expressing plasmid targeting EGFL7 (plegfp-N1-miR-126) was constructed and transiently transfected into ECV-304 cells via liposome. The changes in the mRNA and protein expressions of EGFL7 in the transfected cells were analyzed by fluorescence quantitative RT-PCR and Western blotting., Results: Transfection with the recombinant plasmid plegfp-N1/miR-126 resulted in decreased EGFL7 expression with the passage of time, and the expression reached the lowest level at 48 h after the transfection. The expression of EGFL7 protein was reduced by 67% following the transfection in comparison with the control level, while the transfection with the empty vector resulted in a reduction only by 6.5% relative to the control level., Conclusions: miR-126 can downregulate EGFL7 expression at the protein level in ECV-304 cells.